North America Anticoagulant Reversal Drugs Market Size & Outlook
Related Markets
North America anticoagulant reversal drugs market highlights
- The North America anticoagulant reversal drugs market generated a revenue of USD 533.7 million in 2024.
- The market is expected to grow at a CAGR of 11.6% from 2025 to 2030.
- In terms of segment, idarucizumab was the largest revenue generating product type in 2024.
- Andexanet Alfa is the most lucrative product type segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 533.7 million |
| Market revenue in 2030 | USD 1,027.8 million |
| Growth rate | 11.6% (CAGR from 2025 to 2030) |
| Largest segment | Idarucizumab |
| Fastest growing segment | Andexanet Alfa |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Prothrombin Complex Concentrates, Phytonadione (Vitamin K), Andexanet Alfa, Idarucizumab, Protamine |
| Key market players worldwide | AstraZeneca PLC, Boehringer Ingelheim, CSL Ltd, Bausch Health Companies Inc, Dr Reddy's Laboratories Ltd ADR, Fresenius SE & Co KGaA, Octapharma AG, AMAG Pharmaceuticals, SGPharma, Alps Pharmaceutical Industry Co |
Other key industry trends
- In terms of revenue, North America region accounted for 38.6% of the global anticoagulant reversal drugs market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 666.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anticoagulant Reversal Drugs Market Scope
Anticoagulant Reversal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Alps Pharmaceutical Industry Co | View profile | 251-500 | Hida, Gifu, Japan, Asia | http://www.alps-pharm.co.jp/ |
| SGPharma | View profile | 11-50 | Mumbai, Maharashtra, India, Asia | https://www.sgpharma.com |
| AMAG Pharmaceuticals | View profile | 251-500 | Lexington, Massachusetts, United States, North America | http://www.amagpharma.com |
| Octapharma AG | View profile | 10001+ | Lachen, Schwyz, Switzerland, Europe | http://www.octapharma.com/en.html |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Fresenius SE & Co KGaA | View profile | 193865 | Else-Kroener-Strasse 1, Bad Homburg, HE, Germany, 61352 | https://www.fresenius.com |
| Dr Reddy's Laboratories Ltd ADR | View profile | 22822 | 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, India, 500 034 | https://www.drreddys.com |
North America anticoagulant reversal drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anticoagulant reversal drugs market will help companies and investors design strategic landscapes.
Idarucizumab was the largest segment with a revenue share of 41.26% in 2024. Horizon Databook has segmented the North America anticoagulant reversal drugs market based on prothrombin complex concentrates, phytonadione (vitamin k), andexanet alfa, idarucizumab, protamine covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to North America anticoagulant reversal drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America anticoagulant reversal drugs market databook
-
Our clientele includes a mix of anticoagulant reversal drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America anticoagulant reversal drugs market, including forecasts for subscribers. This continent databook contains high-level insights into North America anticoagulant reversal drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America anticoagulant reversal drugs market size, by country, 2018-2030 (US$M)
North America Anticoagulant Reversal Drugs Market Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
